AI for Drug Discovery Market By Offering (Software, Services);By Technology (Machine Learning and Other Technologies); By Drug Type (Small Molecule and Large Molecules); By Application (Immuno-Oncology, Neurodegenerative Diseases, Cardiovascular Disease, Metabolic Diseases and Other Applications); By End-User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Research Centers and Academic & Government Institutes)and Region – Analysis of Market Size, Share & Trends for 2018 – 2020 and Forecasts to 2030
Market Overview
The initial step in drug discovery is the process of a novel drug candidate’s identification and its therapeutic target base. Based on efficacy, potency, bioavailability, and toxicity the drug discovery or new drug target are being evaluated. Artificial intelligence is extensively used in the healthcare sector and especially used for drug discovery. AI technology has the potential to recognize drug targets, and play an essential role in drug design, discovery, identification, and screening of molecules promptly and efficiently.
Market highlights
The global Artificial Intelligence (AI) in Drug Discovery Market size was valued at USD 253.8 million in 2019 is anticipated to reach USD 3,932.87 million by 2030, demonstrating a CAGR of 40.8 % from 2020 to 2030. AI helps in perceiving the mechanism of disease, establishing biomarkers, and generating data or models for the drug discovery process and thereby expected to propel the market over the forecast period of 2020-2030. Furthermore, rising research and development activities and software launches by the key market players are estimated to spur the market. A wave of new research and development collaborations between key biopharma players and AI-driven companies, mostly startups.
AI for Drug Discovery Market Expected Market Growth
Recent Highlights in Global Digital Banking Platform Market
Lantheus Holdings Inc. a diagnostic imaging company and Progenics Pharmaceuticals Inc. an oncology products company, amended a prior merger in February 2020
Novartis went into a collaboration with Microsoft for the artificial intelligence innovation lab and Amazon Web Services to form an enterprise comprising a data and analytics platform that would yield advanced medicines in February 2020.
A merger with MAbSilico was announced by OSE Immunotherapeutics in February 2020. Innovative problem-solving solutions including artificial intelligence for the development of new monoclonal antibodies are established and incorporated in the merger plan.
Drug Discovery Market: Segments
In 2019, the software segment held the largest share of AI in the drug discovery market of 65.23 percent by type
On the basis of offering type, the AI is segmented into software and services in the drug discovery market. The Software segment accounted for a larger market share in 2018. The growth of the software segment is driven by factors such as lower cost and time to market the drug, low failure rate, a large number of drug discovery software developers, and strong software demand among big pharmaceutical & biotech companies and research institutes.
In the forecast period, the segment of neurodegenerative diseases is projected to rise at the highest CAGR.
Based on the application, the drug discovery market for artificial intelligence is segmented into neurodegenerative diseases, immuno-oncology, cardiovascular disease, metabolic diseases, and other uses. Neurodegenerative diseases form the fastest-growing segment of the application, with the highest CAGR during the forecast period. AI's ability to discover medicines for complex diseases, and market players' focus on offering AI-based neurological disease platforms, is responsible for this application segment's rapid growth.
AI for Drug Discovery Market: Drivers and Restraints
Drivers
Shorten the Drug Discovery Process
Artificial Intelligence is expected as a lucrative healthcare industry avenue. Implementing AI eliminates the research and development gap in the drug production cycle and helps in targeted drug manufacturing as well as helps pharmaceutical companies streamline research and development activities for customized drugs and complex drug discovery. The AI in the Drug Discovery Market is driven by the growing need to shorten the process of drug discovery in order to get drugs to treat various chronic and viral diseases quicker. Due to this, Biopharmaceutical industries tend to increase their market share toward AI.
Declining Cost of the Discovered Drugs
Another factor expected to improve the AI to drug discovery market is the growing pressure on the drugmaker to lower the drug price. Artificial intelligence renders drug discovery more cost-effective and faster. Al lowered the failure rate of clinical trials and also eliminated the cost of long-term drug discovery research and development.
Restraint
High Cost and Lack of Skilled Professionals
Lack of skilled professionals and infrastructure to facilitate easy AI adoption is a major factor that is expected to hamper global AI growth for the drug discovery market. Thus, in addition to limited acceptance by healthcare professionals, high costs and technological limitations of AI decision-making will impede market development.
AI for Drug Discovery Market: Key Players
Microsoft
Company Overview
Business Strategy
Key Product Offerings
Financial Performance
Key Performance Indicators
Risk Analysis
Recent Development
Regional Presence
SWOT Analysis
NVIDIA Corporation
IBM Corporation
Atomwise, Inc
Insilico Medicine
BenevolentAI Ltd
Exscientia
Cyclica Inc
Numerate
NuMedii, Inc
DEEP GENOMICS
Cloud Pharmaceuticals, Inc
Other Prominent Players
AI for Drug Discovery Market: Regions
AI for Drug Discovery Market is segmented based on regional analysis into five major regions. These include North America, Latin America, Europe, APAC, and MENA.
In 2019 North America holds the largest share of AI in the drug discovery market. Additionally, In 2018 North America was the largest and fastest-growing drug discovery market for AI. The US, Canada, and Mexico form the largest drug discovery market for AI. In drug discovery and development these countries were early adopters of AI technology. In the North American market, the US is a major contributor. In addition, leading suppliers of AI technology, such as IBM, Google, Microsoft, NVIDIA, and Intel, are headquartered in the US; their eminent presence is a significant contributor to business growth. Other drivers include the well-established pharmaceutical industry, a strong emphasis on R&D & extensive investment, and the existence of globally prominent pharmaceutical companies. These are a few major factors that are responsible for the large share and high growth rate of this market. Europe is expected to show growth at a remarkable CAGR in the forecast period of 2020-2030. It holds the second-largest market share.
The Asia Pacific region is expected to develop at the highest CAGR of 51.68% over the forecast period, due to perpetual technological advancements in the pharmaceutical sector and the rising number of pharmaceutical manufacturers in developing countries of APAC such as China and India. The initiative of the Indian Government 'Pharma Vision 2020' has a goal for making India a leading hub for drug discovery.
The AI for drug discovery market is further segmented by region into:
North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil, and Rest of Latin America
Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey, and Rest of Europe
APAC Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
MENA Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa, and Rest of MENA
The AI for Drug Discovery Market report also contains analysis on:
AI for Drug Discovery Market Segments:
By Offering
Software
Services
By Drug Type
Small Molecules
Large Molecules
By Technology
Machine Learning
Deep Learning
Supervised Learning
Reinforcement Learning
Unsupervised Learning
Other Machine Learning Technologies
Other Technologies
By Application
Immuno-Oncology
Neurodegenerative Diseases
Cardiovascular Disease
Metabolic Diseases
Other Applications
By End-User
Pharmaceutical & Biotechnology Companies
Contract Research Organizations
Research Centers and Academic & Government Institutes
AI for Drug Discovery Market-Market Dynamics
AI for Drug Discovery Market Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies Involved in the Market
Value Chain of the Market
Market Drivers and Restraints
FAQs on AI for drug discovery Market
Which segment is anticipated to hold the largest market share?
At what CAGR is the market anticipated to grow between 2020 and 2030?
Who are the key players in the AI for the drug discovery market?
What could be the challenging factors for the growth of AI for the drug discovery market?
What are the growth drivers for AI for the drug discovery market?
The initial step in drug discovery is the process of a novel drug candidate’s identification and its therapeutic target base. Based on efficacy, potency, bioavailability, and toxicity the drug discovery or new drug target are being evaluated. Artificial intelligence is extensively used in the healthcare sector and especially used for drug discovery. AI technology has the potential to recognize drug targets, and play an essential role in drug design, discovery, identification, and screening of molecules promptly and efficiently.
Market highlights
The global Artificial Intelligence (AI) in Drug Discovery Market size was valued at USD 253.8 million in 2019 is anticipated to reach USD 3,932.87 million by 2030, demonstrating a CAGR of 40.8 % from 2020 to 2030. AI helps in perceiving the mechanism of disease, establishing biomarkers, and generating data or models for the drug discovery process and thereby expected to propel the market over the forecast period of 2020-2030. Furthermore, rising research and development activities and software launches by the key market players are estimated to spur the market. A wave of new research and development collaborations between key biopharma players and AI-driven companies, mostly startups.
AI for Drug Discovery Market Expected Market Growth
Recent Highlights in Global Digital Banking Platform Market
Lantheus Holdings Inc. a diagnostic imaging company and Progenics Pharmaceuticals Inc. an oncology products company, amended a prior merger in February 2020
Novartis went into a collaboration with Microsoft for the artificial intelligence innovation lab and Amazon Web Services to form an enterprise comprising a data and analytics platform that would yield advanced medicines in February 2020.
A merger with MAbSilico was announced by OSE Immunotherapeutics in February 2020. Innovative problem-solving solutions including artificial intelligence for the development of new monoclonal antibodies are established and incorporated in the merger plan.
Drug Discovery Market: Segments
In 2019, the software segment held the largest share of AI in the drug discovery market of 65.23 percent by type
On the basis of offering type, the AI is segmented into software and services in the drug discovery market. The Software segment accounted for a larger market share in 2018. The growth of the software segment is driven by factors such as lower cost and time to market the drug, low failure rate, a large number of drug discovery software developers, and strong software demand among big pharmaceutical & biotech companies and research institutes.
In the forecast period, the segment of neurodegenerative diseases is projected to rise at the highest CAGR.
Based on the application, the drug discovery market for artificial intelligence is segmented into neurodegenerative diseases, immuno-oncology, cardiovascular disease, metabolic diseases, and other uses. Neurodegenerative diseases form the fastest-growing segment of the application, with the highest CAGR during the forecast period. AI's ability to discover medicines for complex diseases, and market players' focus on offering AI-based neurological disease platforms, is responsible for this application segment's rapid growth.
AI for Drug Discovery Market: Drivers and Restraints
Drivers
Shorten the Drug Discovery Process
Artificial Intelligence is expected as a lucrative healthcare industry avenue. Implementing AI eliminates the research and development gap in the drug production cycle and helps in targeted drug manufacturing as well as helps pharmaceutical companies streamline research and development activities for customized drugs and complex drug discovery. The AI in the Drug Discovery Market is driven by the growing need to shorten the process of drug discovery in order to get drugs to treat various chronic and viral diseases quicker. Due to this, Biopharmaceutical industries tend to increase their market share toward AI.
Declining Cost of the Discovered Drugs
Another factor expected to improve the AI to drug discovery market is the growing pressure on the drugmaker to lower the drug price. Artificial intelligence renders drug discovery more cost-effective and faster. Al lowered the failure rate of clinical trials and also eliminated the cost of long-term drug discovery research and development.
Restraint
High Cost and Lack of Skilled Professionals
Lack of skilled professionals and infrastructure to facilitate easy AI adoption is a major factor that is expected to hamper global AI growth for the drug discovery market. Thus, in addition to limited acceptance by healthcare professionals, high costs and technological limitations of AI decision-making will impede market development.
AI for Drug Discovery Market: Key Players
Microsoft
Company Overview
Business Strategy
Key Product Offerings
Financial Performance
Key Performance Indicators
Risk Analysis
Recent Development
Regional Presence
SWOT Analysis
NVIDIA Corporation
IBM Corporation
Atomwise, Inc
Insilico Medicine
BenevolentAI Ltd
Exscientia
Cyclica Inc
Numerate
NuMedii, Inc
DEEP GENOMICS
Cloud Pharmaceuticals, Inc
Other Prominent Players
AI for Drug Discovery Market: Regions
AI for Drug Discovery Market is segmented based on regional analysis into five major regions. These include North America, Latin America, Europe, APAC, and MENA.
In 2019 North America holds the largest share of AI in the drug discovery market. Additionally, In 2018 North America was the largest and fastest-growing drug discovery market for AI. The US, Canada, and Mexico form the largest drug discovery market for AI. In drug discovery and development these countries were early adopters of AI technology. In the North American market, the US is a major contributor. In addition, leading suppliers of AI technology, such as IBM, Google, Microsoft, NVIDIA, and Intel, are headquartered in the US; their eminent presence is a significant contributor to business growth. Other drivers include the well-established pharmaceutical industry, a strong emphasis on R&D & extensive investment, and the existence of globally prominent pharmaceutical companies. These are a few major factors that are responsible for the large share and high growth rate of this market. Europe is expected to show growth at a remarkable CAGR in the forecast period of 2020-2030. It holds the second-largest market share.
The Asia Pacific region is expected to develop at the highest CAGR of 51.68% over the forecast period, due to perpetual technological advancements in the pharmaceutical sector and the rising number of pharmaceutical manufacturers in developing countries of APAC such as China and India. The initiative of the Indian Government 'Pharma Vision 2020' has a goal for making India a leading hub for drug discovery.
The AI for drug discovery market is further segmented by region into:
North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil, and Rest of Latin America
Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey, and Rest of Europe
APAC Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
MENA Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa, and Rest of MENA
The AI for Drug Discovery Market report also contains analysis on:
AI for Drug Discovery Market Segments:
By Offering
Software
Services
By Drug Type
Small Molecules
Large Molecules
By Technology
Machine Learning
Deep Learning
Supervised Learning
Reinforcement Learning
Unsupervised Learning
Other Machine Learning Technologies
Other Technologies
By Application
Immuno-Oncology
Neurodegenerative Diseases
Cardiovascular Disease
Metabolic Diseases
Other Applications
By End-User
Pharmaceutical & Biotechnology Companies
Contract Research Organizations
Research Centers and Academic & Government Institutes
AI for Drug Discovery Market-Market Dynamics
AI for Drug Discovery Market Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies Involved in the Market
Value Chain of the Market
Market Drivers and Restraints
FAQs on AI for drug discovery Market
Which segment is anticipated to hold the largest market share?
At what CAGR is the market anticipated to grow between 2020 and 2030?
Who are the key players in the AI for the drug discovery market?
What could be the challenging factors for the growth of AI for the drug discovery market?
What are the growth drivers for AI for the drug discovery market?
1. EXECUTIVE SUMMARY
2. AI FOR DRUG DISCOVERY
2.1. AI for Drug Discovery Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. RESEARCH METHODOLOGY
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. AVERAGE PRICING ANALYSIS
5. MARKET DYNAMICS
5.1. Growth Drivers
5.2. Restraints
5.3. Opportunity
5.4. Trends
6. RECENT DEVELOPMENT, POLICIES & REGULATORY LANDSCAPE
7. RISK ANALYSIS
7.1. Demand Risk Analysis
7.2. Supply Risk Analysis
8. AI FOR DRUG DISCOVERY INDUSTRY ANALYSIS
8.1. Porters Five Forces
8.1.1. Threat of New Entrants
8.1.2. Bargaining Power of Suppliers
8.1.3. Threat of Substitutes
8.1.4. Rivalry
8.2. PEST Analysis
8.2.1. Political
8.2.2. Economic
8.2.3. Social
8.2.4. Technological
9. GLOBAL AI FOR DRUG DISCOVERY MARKET
9.1. Market Size & forecast, 2019A-2030F
9.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
9.1.2. By Volume (Million Units) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10. GLOBAL AI FOR DRUG DISCOVERY: MARKET SEGMENTATION
10.1. By Regions
10.1.1. North America: (U.S. and Canada)
10.1.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America)
10.1.2.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe)
10.1.3.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific)
10.1.4.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa)
10.1.5.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.2. By Offering: Market Share (2020-2030F)
10.2.1. Software, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.2.2. Services, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.3. By Drug Type: Market Share (2020-2030F)
10.3.1. Small Molecule, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.3.2. Large Molecules, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.4. By Technology: Market Share (2020-2030F)
10.4.1. Machine Learning, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.4.2. Other Technologies, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.5. By Application: Market Share (2020-2030F)
10.5.1. Immuno-Oncology, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.5.2. Neurodegenerative Diseases, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.5.3. Cardiovascular Disease, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.5.4. Metabolic Diseases, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.5.5. Other Applications, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.6. By End-users: Market Share (2020-2030F)
10.6.1. Pharmaceutical & Biotechnology Companies, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.6.2. Contract Research Organizations, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.6.3. Research Centers, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.6.4. Academic & Government Institutes, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11. COMPANY PROFILE
11.1. Microsoft
11.1.1. Company Overview
11.1.2. Company Total Revenue (Financials)
11.1.3. Market Potential
11.1.4. Global Presence
11.1.5. Key Performance Indicators
11.1.6. SWOT Analysis
11.1.7. Product Launch
11.2. NVIDIA Corporation
11.3. IBM Corporation
11.4. Atomwise, Inc
11.5. Insilico Medicine
11.6. BenevolentAI Ltd
11.7. Exscientia
11.8. Cyclica Inc
11.9. Numerate
11.10. NuMedii, Inc
11.11. DEEP GENOMICS
11.12. Cloud Pharmaceuticals, Inc
Consultant Recommendation
**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
2. AI FOR DRUG DISCOVERY
2.1. AI for Drug Discovery Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. RESEARCH METHODOLOGY
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. AVERAGE PRICING ANALYSIS
5. MARKET DYNAMICS
5.1. Growth Drivers
5.2. Restraints
5.3. Opportunity
5.4. Trends
6. RECENT DEVELOPMENT, POLICIES & REGULATORY LANDSCAPE
7. RISK ANALYSIS
7.1. Demand Risk Analysis
7.2. Supply Risk Analysis
8. AI FOR DRUG DISCOVERY INDUSTRY ANALYSIS
8.1. Porters Five Forces
8.1.1. Threat of New Entrants
8.1.2. Bargaining Power of Suppliers
8.1.3. Threat of Substitutes
8.1.4. Rivalry
8.2. PEST Analysis
8.2.1. Political
8.2.2. Economic
8.2.3. Social
8.2.4. Technological
9. GLOBAL AI FOR DRUG DISCOVERY MARKET
9.1. Market Size & forecast, 2019A-2030F
9.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
9.1.2. By Volume (Million Units) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10. GLOBAL AI FOR DRUG DISCOVERY: MARKET SEGMENTATION
10.1. By Regions
10.1.1. North America: (U.S. and Canada)
10.1.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America)
10.1.2.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe)
10.1.3.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific)
10.1.4.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa)
10.1.5.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.2. By Offering: Market Share (2020-2030F)
10.2.1. Software, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.2.2. Services, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.3. By Drug Type: Market Share (2020-2030F)
10.3.1. Small Molecule, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.3.2. Large Molecules, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.4. By Technology: Market Share (2020-2030F)
10.4.1. Machine Learning, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.4.2. Other Technologies, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.5. By Application: Market Share (2020-2030F)
10.5.1. Immuno-Oncology, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.5.2. Neurodegenerative Diseases, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.5.3. Cardiovascular Disease, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.5.4. Metabolic Diseases, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.5.5. Other Applications, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.6. By End-users: Market Share (2020-2030F)
10.6.1. Pharmaceutical & Biotechnology Companies, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.6.2. Contract Research Organizations, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.6.3. Research Centers, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.6.4. Academic & Government Institutes, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11. COMPANY PROFILE
11.1. Microsoft
11.1.1. Company Overview
11.1.2. Company Total Revenue (Financials)
11.1.3. Market Potential
11.1.4. Global Presence
11.1.5. Key Performance Indicators
11.1.6. SWOT Analysis
11.1.7. Product Launch
11.2. NVIDIA Corporation
11.3. IBM Corporation
11.4. Atomwise, Inc
11.5. Insilico Medicine
11.6. BenevolentAI Ltd
11.7. Exscientia
11.8. Cyclica Inc
11.9. Numerate
11.10. NuMedii, Inc
11.11. DEEP GENOMICS
11.12. Cloud Pharmaceuticals, Inc
Consultant Recommendation
**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
